FDA approves single-pill regimen HIV med

|By:, SA News Editor

The FDA clears ViiV Healthcare's Triumeq (abacavir 600 mg, dolutegravir 50 mg, lamivudine 300 mg) for the treatment of HIV-1 infection. The single-pill regimen combines the integrase strand transfer inhibitor dolutegravir with the nucleoside reverse transcriptase inhibitors abacavir and lamivudine.

ViiV Healthcare is an HIV-focused company established in 2009 by GlaxoSmithKline (GSK -1.6%) and Pfizer (PFE +0.5%). Shionogi joined the venture in October 2012.